Printer Friendly

Mayne Pharma Group Limited passes US FDA approval for trade name Lexette (halobetasol propionate) foam, 0.05%.

Global Banking News-May 1, 2019-Mayne Pharma Group Limited passes US FDA approval for trade name Lexette (halobetasol propionate) foam, 0.05%

(C)2019 ENPublishing - http://www.enpublishing.co.uk

Pharmaceutical company Mayne Pharma Group Limited (ASX:MYX) revealed on Tuesday that the US Food and Drug Administration (FDA) has approved the trade name LEXETTE for the approved drug halobetasol propionate foam, 0.05% for the treatment of plaque psoriasis in adult patients.

Plaque psoriasis affects approximately 7.5 million Americans with potent topical corticosteroids prescribed to approximately 80% of psoriasis patients diagnosed. LEXETTE is part of the USD600m potent topical corticosteroid market for which 8m prescriptions are written annually.

LEXETTE is a new formulation of halobetasol, a potent topical corticosteroid, which is indicated for the treatment of plaque psoriasis in adult patients, added the company.

The company made the US FDA approved halobetasol foam available to US patients before it received a trade name. It is now available under the trade name LEXETTE.

((Distributed via M2 Communications - http://www.m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Global Banking News (GBN)
Date:May 1, 2019
Words:171
Previous Article:Basware is planning to launch a productivity programme.
Next Article:DSV's board decides to launch DKK3,500m share buyback programme.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |